Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

Joyce O’shaughnessy, Katarina Petrakova, Gabe S. Sonke, Pierfranco Conte, Carlos L. Arteaga, David A. Cameron, Lowell L. Hart, Cristian Villanueva, Erik Jakobsen, Joseph T. Beck, Deborah Lindquist, Farida Souami, Shoubhik Mondal, Caroline Germa, Gabriel N. Hortobagyi

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalBreast cancer research and treatment
DOIs
Publication statusPublished - 21 Nov 2017

Keywords / Materials (for Non-textual outputs)

  • breast cancer
  • CDK inhibitor
  • Ribociclib
  • Endocrine therapy
  • De novo advanced breast cancer
  • Hormon receptor positive

Cite this